Nissay Asset Management Corp Nektar Therapeutics Transaction History

Nissay Asset Management Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $15,185 - $32,570	898 Added 6.19%	15,404 $281,000
Q2 2019 Aug 07, 2019	BUY	$31.0 - $36.3 $4,154 - $4,864	134 Added 0.93%	14,506 $516,000
Q1 2019 May 03, 2019	BUY	$31.58 - $46.35 $23,053 - $33,835	730 Added 5.35%	14,372 $483,000
Q4 2018 Feb 06, 2019	SELL	$30.43 - $56.65 $300,222 - $558,908	-9,866 Reduced 41.97%	13,642 $448,000
Q3 2018 Oct 30, 2018	BUY	$46.46 - $68.49 $500,792 - $738,253	10,779 Added 84.68%	23,508 $1.43 Million
Q2 2018 Aug 08, 2018	BUY	$46.25 - $104.45 $588,716 - $1.33 Million	12,729 New	12,729 $622,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.